The use of alternate-day lovastatin in hypercholesterolemic men

Annals of Pharmacotherapy

Volumn 31, Issue 6, 1997, Pages 708-712

  Dennis, Vincent C ^a,b,e   Britton, Mark L ^c   Sirmans, Susan M ^b,c   Letassy, Nancy A ^b,c   Freeman, Dale A ^c,d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

^d UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^e Norman Regional Hospital   (United States)

Author keywords

Hypercholesterolemia; Lipoprotein; Lovastatin

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HYPERCHOLESTEROLEMIA; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 0030987902     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809703100607     Document Type: Article

References (13)

1. Package insert. Mevacor (lovastatin). West Point, PA: Merck and Co., Inc., 1995.
2. Tobert JA, Bell GD, Birtwell J, James I, Kukovetz WR, Pryor JS, et al. Cholesterol lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, in healthy volunteers. J Clin Invest 1982;69:913-9.
3. Hunninghake L, Miller VT, Palmer RH, Schonfield G, Stein EA, Tobert JA, et al. Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia: a multicenter study. The Lovastatin Study Group II. JAMA 1986;256:2829-34.
4. Tobert JA, Shapiro DR, Keegan ME, Gutwein TM, Pappas F, Machey B, et al. Lovastatin 5-year safety and efficacy study. Arch Intern Med 1993;153:1079-87.
5. Bradford RH, Shear CL, Chremos AN, Dujovne C, Franklin FA, Hesney M, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study: design and patient characteristics of a double-blind, placebo-controlled study in patients with moderate hypercholesterolemia. Am J Cardiol 1990;66(suppl):44B-55B.
6. Bradford RH, Shear CL, Chremos AN, Dujovne C, Downton M, Franklin FA, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8,425 patients with moderate hypercholesterolemia. Am J Med 1991; 151:43-9.
7. Bradford RH, Shear CL, Chremos AN, Franklin FA, Nash DT, Hurley DP, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. III. Efficacy in modifying lipoproteins and implications for managing patients with moderate hypercholesterolemia. Am J Med 1991;91 (suppl):18S-24S.
8. Rindone JP, Achacoso R, Bledsoe R. Effect of lovastatin administered every other day on serum low-density lipoprotein cholesterol >160 mg/dL. Am J Cardiol 1995;76:312-3.
9. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
10. National Cholesterol Education Program Expert Panel. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med 1998;148:36-69.
11. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel D). JAMA 1993;269:3015-23.
12. Cardinale V, ed. Drug topics red book. Montvale, NJ: Medical Economics Company, Inc., 1996:352.
13. Rubinstein A, Lurie Y, Groskop I, Weintrob M. Cholesterol lowering effects of a 10 mg daily dose of lovastatin in patients with initial total cholesterol levels 200 to 240 mg/dL (5.18 to 6.21 mmol/liter). Am J Cardiol 1991;68:1123-6.